LINAC2022 - List of Authors (van Garderen, E.D.)

Paper	Title	Page
MOPOGE10	A Medical Linac for Affordable Proton Therapy	167
MOOPA05	use link to see paper's listing under its alternate paper code
	S. Hunt, J. Adélise, W.D. Klotz, R. Seviour, E.D. van Garderen Alceli Limited, Newhouse, United Kingdom D. Correia PSI, Villigen PSI, Switzerland
	Proton Therapy (PT) was first proposed in the 1940s. Application of this knowledge was largely led over the next fifty years by accelerator laboratories, but now also by commercial companies. Availability of PT is increasing but is limited by three factors: facility size, prompt/induced radiation, and treatment cost. Compact cyclotrons/synchro cyclotrons for single-room facilities have reduced space requirements. linacs can avoid high radiation levels. Yet treatment costs have remained stubbornly high, driven largely by maintenance and staffing costs over the typical 20-30 year facility lifetime. Current technology cannot simultaneously reduce these three factors. By using a long linac, the Alceli approach sacrifices size limitations, to gain massive improvements in treatment cost and radiation levels. Quadrupling the length of a linac results in a sixteen-fold reduction in RF power per cavity. Along with other innovations in our design, this leads to a modular warm linac with distributed solid-state RF amplification, easy and cheap to manufacture and maintain, requiring no water cooling, and a treatment cost of 1/10th of current facilities, making PT much more affordable.
	Slides MOPOGE10 [1.934 MB]
DOI •	reference for this paper ※ https://doi.org/10.18429/JACoW-LINAC2022-MOPOGE10
About •	Received ※ 15 August 2022 — Revised ※ 23 August 2022 — Accepted ※ 29 August 2022 — Issue date ※ 01 September 2022
Cite •	reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)

Paper

Title

Page

MOPOGE10

A Medical Linac for Affordable Proton Therapy

167

MOOPA05

use link to see paper's listing under its alternate paper code

S. Hunt, J. Adélise, W.D. Klotz, R. Seviour, E.D. van Garderen
Alceli Limited, Newhouse, United Kingdom
D. Correia
PSI, Villigen PSI, Switzerland

Proton Therapy (PT) was first proposed in the 1940s. Application of this knowledge was largely led over the next fifty years by accelerator laboratories, but now also by commercial companies. Availability of PT is increasing but is limited by three factors: facility size, prompt/induced radiation, and treatment cost. Compact cyclotrons/synchro cyclotrons for single-room facilities have reduced space requirements. linacs can avoid high radiation levels. Yet treatment costs have remained stubbornly high, driven largely by maintenance and staffing costs over the typical 20-30 year facility lifetime. Current technology cannot simultaneously reduce these three factors. By using a long linac, the Alceli approach sacrifices size limitations, to gain massive improvements in treatment cost and radiation levels. Quadrupling the length of a linac results in a sixteen-fold reduction in RF power per cavity. Along with other innovations in our design, this leads to a modular warm linac with distributed solid-state RF amplification, easy and cheap to manufacture and maintain, requiring no water cooling, and a treatment cost of 1/10th of current facilities, making PT much more affordable.

Slides MOPOGE10 [1.934 MB]

DOI •

reference for this paper ※ https://doi.org/10.18429/JACoW-LINAC2022-MOPOGE10

About •

Received ※ 15 August 2022 — Revised ※ 23 August 2022 — Accepted ※ 29 August 2022 — Issue date ※ 01 September 2022

Cite •

reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)